Recent Posts

• Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)
• Genascence to Present at Biotech Showcase 2024
• Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress
• Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer
• Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis